Vineti Stock
Cell & Gene Therapy Software
Sign up today and learn more about Vineti Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Vineti Stock
Vineti is a commercial cloud-based platform to expand patient access to life-saving cells and gene therapies. It is a software solution to drive and scale personalized therapeutic innovation. It solves the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Founded in 2016, Vineti is headquartered in San Francisco, California.
Investors
Canaan Partners
Instacart, Snyk, Dragos, Turo, The RealReal, MindTickle, Lending Club, Berkshire Grey, Tomorrow.io, Apartment List
Cardinal Health
LifeForce Capital
Cityblock Health, HeartFlow, One Medical, Clover Health, Grand Rounds Health, Vineti, Verge Genomics
HIVE Ventures
Section 32
Celularity, Freenome, Dialpad, Lime, Metromile, Primer, Vineti, Kobalt, BigHat Biosciences
Funding History
February 2017 | $14.1M |
---|---|
April 2018 | $33.5M |
January 2020 | $31K |
January 2020 | $75.2M |
July 2020 | $94K |
Management
Chief Executive Officer
Amy DuRoss
Chief Financial Officer
Brett Robertson
Chief Technology Officer
Phil Calvin
Press
techcompanynews - Oct, 30 2020
An Interview With Amy DuRoss, CEO And Co-Founder Of Vinetibusinessinsider - Oct, 17 2020
Here's the pitch deck that convinced Salesforce CEO Marc Benioff to participate in a $33 million Series C extension for Vineti, which makes cloud software to track advanced drug developmentfinsmes - Oct, 15 2020
Vineti Raises $33M; Extends Series C Funding to $68Mvcaonline - Oct, 14 2020
Venture Capital Database 2020 Now Available!digitaljournal - Jun, 20 2020
New Alliance Network for cell and gene therapies